Psychemedics (PMDI)
OTHER OTC:PMDI
Top Page
No summary available
Positive Factors
Patented Technology
Psychemedics' patented hair testing technology provides a competitive advantage by offering a longer detection window, enhancing its market position in drug testing.
Negative Factors
Declining Revenues
Persistent revenue decline suggests challenges in market demand or competition, which could impact long-term growth and profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Patented Technology
Psychemedics' patented hair testing technology provides a competitive advantage by offering a longer detection window, enhancing its market position in drug testing.
Read all positive factors
Psychemedics (PMDI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.36M
Dividend YieldN/A
Average Volume (3M)375.00
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth-10.92%
EPS Growth55.62%
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryMedical Diagnostics & Screening
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,119,477
10 Day Avg. Volume472
30 Day Avg. Volume375
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Psychemedics Business Overview & Revenue Model
Company Description
Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, sc...
How the Company Makes Money
Psychemedics Corporation generates revenue primarily through the provision of drug testing services. The company charges its clients, which include corporations, government agencies, and educational institutions, for conducting hair analysis tests...
Psychemedics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 8.41M | 9.29M | 10.26M | 4.89M | 16.44M |
| EBITDA | -251.00K | 2.23M | 3.90M | -2.44M | 6.03M |
| Net Income | -4.15M | -1.08M | -665.00K | -3.86M | 1.54M |
Balance Sheet | |||||
| Total Assets | 12.33M | 18.73M | 21.55M | 24.00M | 27.53M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 2.30M | 3.57M | 5.13M | 8.90M | 5.97M |
| Total Liabilities | 5.65M | 7.96M | 9.31M | 11.49M | 10.71M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -1.64M | 4.70M | 232.00K | -4.93M | 2.58M |
| Operating Cash Flow | -1.48M | 4.89M | 414.00K | -4.08M | 4.31M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Psychemedics Technical Analysis
Positive
2.02
Price Trends
1.59
Positive
1.69
Positive
1.94
Positive
Market Momentum
0.10
Negative
82.18
Negative
98.50
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMDI, the sentiment is Positive. The current price of 2.02 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.59, and above the 200-day MA of 1.94, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 82.18 is Negative, neither overbought nor oversold. The STOCH value of 98.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMDI.
Psychemedics Risk Analysis
Psychemedics disclosed 26 risk factors in its most recent earnings report. Psychemedics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Psychemedics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $12.36M | -6.30 | ― | ― | -10.92% | 55.62% | |
54 Neutral | $31.11M | -1.12 | -85.01% | ― | -16.59% | 43.20% | |
53 Neutral | $17.63M | -0.14 | -245.18% | ― | -27.66% | 13.18% | |
48 Neutral | $12.28M | -0.56 | -406.72% | ― | ― | 57.97% | |
46 Neutral | $23.73M | -33.14 | 0.27% | ― | 75.19% | ― | |
44 Neutral | $24.34M | -1.88 | >-0.01% | ― | -12.99% | -13.67% |
* Healthcare Sector Average
PMDI
Psychemedics
2.02
-0.24
-10.62%
IMNN
Imunon
3.13
-8.22
-72.42%
TXMD
TherapeuticsMD
2.05
1.16
130.34%
EKSO
EKSO BIONICS
8.73
2.77
46.48%
MRKR
Marker Therapeutics
1.46
0.39
36.45%
BIAF
bioAffinity Technologies, Inc.
3.92
-14.85
-79.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―